Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.

Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW.

Clin Cancer Res. 2018 May 21. doi: 10.1158/1078-0432.CCR-17-3279. [Epub ahead of print]

PMID:
29784675
2.

Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.

Li A, Barsoumian HB, Schoenhals JE, Cushman TR, Caetano MS, Wang X, Valdecanas DR, Niknam S, Younes AI, Li G, Woodward WA, Cortez MA, Welsh JW.

Cancer Lett. 2018 Sep 1;431:54-63. doi: 10.1016/j.canlet.2018.05.005. Epub 2018 May 8.

PMID:
29746927
3.

Radiation therapy and immunotherapy: what is the optimal timing or sequencing?

Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, Barsoumian HB, Younes AI, K Mahadevan LS, Soeung M, Aziz KE, Welsh JW, Krishnan S.

Immunotherapy. 2018 Feb 1;10(4):299-316. doi: 10.2217/imt-2017-0082.

PMID:
29421979
4.

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.

Schoenhals JE, Seyedin SN, Anderson C, Brooks ED, Li YR, Younes AI, Niknam S, Li A, Barsoumian HB, Cortez MA, Welsh JW.

Transl Lung Cancer Res. 2017 Apr;6(2):148-158. doi: 10.21037/tlcr.2017.03.06. Review.

5.

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.

Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU.

J Thorac Oncol. 2017 Feb;12(2):375-382. doi: 10.1016/j.jtho.2016.10.013. Epub 2016 Oct 26.

Supplemental Content

Loading ...
Support Center